Logo
  • About Us
    • Key Advisors
    • Leadership Team
    • Board of Directors
    • Vision / Mission
  • Products & Services
  • Therapeutic Pipeline
  • Biosort AI
  • Media
    • News
    • Videos/Podcasts
    • Key Industry Deals
    • Blog
  • Contact Us
    • Contact
  • White Paper: Industrial Scale Microbiome Mining...

Follow Us linked In
Logo
  • About Us
    • Key Advisors
    • Leadership Team
    • Board of Directors
    • Vision / Mission
  • Products & Services
  • Therapeutic Pipeline
  • Biosort AI
  • Media
    • News
    • Videos/Podcasts
    • Key Industry Deals
    • Blog
  • Contact Us
    • Contact
  • White Paper: Industrial Scale Microbiome Mining...

Follow Us linked In
2025 August
  • Home
  • Archive for August, 2025
Global Trial Podcast
user

Host: Julio Martinez linkedin-img

user

Guest: Ross Youngs linkedin-img


×

Global Trial Accelerators™: Fast-Tracking First-in-Human Trials, Anywhere

  • August 29 2025
  • Video - Date: 08/28/2025
  • Length: 29.44

Summary –

Discussed in this Podcast

→ How microbiome mining could cure cancer, Alzheimer’s & more
→ Processing 2 MILLION liters of water daily to extract microbes
→ Accessing drug-like molecules that evolution perfected over 3.4 billion years
→ Why this could be worth TRILLIONS in the next 25 years
→ Transforming agriculture, cosmetics & environmental remediation

lightbulbKEY TAKEAWAY: “Microbes have always been chemical researchers and factories of life. Biosortia’s breakthrough technology now effectively opens the door to ALL microbes.” – Ross Youngs

This technology could literally transform how we discover new medicines and accelerate first-in human trials globally!

Lilly signs $1.3 billion deal with Superluminal to discover obesity medicines using AI

  • August 15 2025

Lilly signs $1.3 billion deal with Superluminal to discover obesity medicines using AI (August 15, 2025) by Mariam E Sunny. Summary Superluminal to receive payments, equity investment, royalties Lilly, Novo pursuing GPCR-targeting drugs for obesity Superluminal’s lead candidate not part of deal with Lilly. Aug 14 (Reuters) – Eli Lilly (LLY.N), has signed a deal worth $1.3 billion with privately

Continue Reading

Superluminal Medicines Announces Collaboration with Eli Lilly and Company to Advance Small Molecule Therapeutics for Cardiometabolic Diseases and Obesity

  • August 14 2025

Superluminal Medicines Announces Collaboration with Eli Lilly and Company to Advance Small Molecule Therapeutics for Cardiometabolic Diseases and Obesity Collaboration focused on undisclosed GPCR targets Company to receive an upfront and near-term payments, including an equity investment, as well as additional development and commercial milestones, and tiered royalties (August 14, 2025) by Sarah Sutton. Boston, MA — August 14, 2025

Continue Reading

RSS Industry News

  • Red palm olein biscuit supplementation modulates gut microbiota in vitamin A deficient rural Malaysian schoolchildren: a randomised controlled trial October 22 2025
  • Long-read metagenomics for strain tracking after faecal microbiota transplant October 22 2025
  • Microbial metabolite indole-3-propionic acid drives mitochondrial respiration in CD4+ T cells to confer protection against intestinal inflammation October 21 2025
  • Activity-targeted metaproteomics uncovers rare syntrophic bacteria central to anaerobic community metabolism October 21 2025
  • IPA brews metabolic balance in gut immunity October 21 2025
  • Multiple sclerosis patients exhibit oral dysbiosis with decreased early colonizers and lower hypotaurine level October 20 2025
  • Exploring colostrum microbiota and its influence on early calf gut microbiota development using full-length 16S rRNA gene metabarcoding October 17 2025
  • Drought-tolerant rhizobacteria boost crop resilience October 17 2025
  • Predicting functions of uncharacterized gene products from microbial communities October 15 2025
  • Isolation, engineering and ecology of temperate phages from the human gut October 15 2025
Quick Link
  • Products & Services
  • Blog
  • Contact
Recent Posts
  • The Evolutionary Advantage: Why Microbial Chemistry Wins in Drug Discovery & Approval
  • White Paper — The Beauty of Microbial Natural Products: Selective Polypharmacology ≠ Promiscuity
  • Takeda turns to AI drug designer for $1B biobucks deal after whittling down R&D focus
Sign up for our newsletter
Loading
Biosortia Microbiomics © 2024. All Rights Reserved